{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:33:49Z","timestamp":1762659229852,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.biopha.2012.11.004","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T15:50:13Z","timestamp":1353685813000},"page":"103-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia"],"prefix":"10.1016","volume":"67","author":[{"given":"Jeany","family":"Camelo-Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"do Prado Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisangela","family":"de Paula Silveira-Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia Andreu","family":"Guillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.11.004_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-200767020-00010","article-title":"Imatinib: a review of its use in chronic myeloid leukaemia","volume":"67","author":"Moen","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2012.11.004_bib0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/era.12.10","article-title":"Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"12","author":"Karvela","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.biopha.2012.11.004_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hanctschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.11.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2012.03.005","article-title":"The expanding options for front-line treatment of patients with newly diagnosed CML","author":"Pinilla-Ibarz","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0030","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-4-(2-hydroyethyl)-piperazin-1-yl)-(2-mehtylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopha.2012.11.004_bib0035","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.11.004_bib0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clinthera.2010.05.003","article-title":"Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib","volume":"32","author":"Stein","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.biopha.2012.11.004_bib0045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.11.004_bib0050","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.11.004_bib0055","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14656566.2012.672974","article-title":"Tyrosine kinase inhibitors in acute and chronic leukemias","volume":"13","author":"Ohanian","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biopha.2012.11.004_bib0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11899-011-0087-9","article-title":"Predicting the response of CML patients to tyrosine kinase inhibitor therapy","volume":"6","author":"White","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.biopha.2012.11.004_bib0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"faltam... A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"Mc Weeney","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.11.004_bib0070","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/sj.onc.1207428","article-title":"Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo","volume":"23","author":"Sullivan","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2012.11.004_bib0075","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1158\/1078-0432.CCR-04-1547","article-title":"Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs","volume":"11","author":"Vikhanskaya","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.11.004_bib0195","first-page":"961","article-title":"Primary structure polymorphism at amino acid residue 72 of human p53","volume":"7","author":"Matlashewski","year":"1987","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.onc.1205015","article-title":"The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells","volume":"21","author":"Baptiste","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2012.11.004_bib0090","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","article-title":"The codon 72 polymorphic variants of p53 have markedly different apoptotic potential","volume":"33","author":"Dumont","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.biopha.2012.11.004_bib0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7314\/APJCP.2012.13.1.349","article-title":"TP53 codon 72 polymorphism and risk of acute leukemia","volume":"13","author":"Dunna","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.biopha.2012.11.004_bib0100","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.leukres.2009.04.007","article-title":"Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia","volume":"33","author":"Xiong","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.biopha.2012.11.004_bib0105","first-page":"868","article-title":"TP53 codon 72 polymorphism in patients with chronic myeloid leukemia","volume":"89","author":"Bergamaschi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2012.11.004_bib0110","first-page":"316","article-title":"TP53 codon 72 polymorphism and risk of chronic myeloid leukemia","volume":"13","author":"Sailaja","year":"2009","journal-title":"Gene Ther Mol Biol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0115","first-page":"346","article-title":"Codon 72 polymorphism of the TP53 gene in patients suspected to have CML","volume":"29","author":"Ham\u00fa","year":"2007","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.biopha.2012.11.004_bib0120","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.32635\/2176-9745.RBC.2003v49n1.2130","article-title":"Condutas do INCA: Leucemia miel\u00f3ide cr\u00f4nica","volume":"49","author":"National Cancer Institute (INCA)","year":"2003","journal-title":"Rev Bras Cancerol"},{"key":"10.1016\/j.biopha.2012.11.004_bib0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.11.004_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2011.02.001","article-title":"Interpretation of cytogenetic and molecular results in patients treated for CML","volume":"25","author":"Vigil","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.biopha.2012.11.004_bib0140","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"N Engl J Med"},{"year":"1989","series-title":"Molecular cloning: a laboratory manual (second ed.)","author":"Sambrook","key":"10.1016\/j.biopha.2012.11.004_bib0145"},{"key":"10.1016\/j.biopha.2012.11.004_bib0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/30400","article-title":"Role of p53 polymorphism in the development of human papiloma-virus-associated cancer","volume":"393","author":"Storey","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2012.11.004_bib0155","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: a web tool for the analysis of association studies","volume":"22","author":"Sole","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2012.11.004_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12038-012-9183-9","article-title":"TP53 codon 72 polymorphism in pigmentary phenotypes","volume":"37","author":"Costa","year":"2012","journal-title":"J Biosci"},{"key":"10.1016\/j.biopha.2012.11.004_bib0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1582-4934.2008.00634.x","article-title":"Polymorphisms in p53 and the p53 pathways: roles in cancer susceptibility and response to treatment","volume":"13","author":"Hrstka","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.biopha.2012.11.004_bib0170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.leukres.2005.12.014","article-title":"Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia","volume":"30","author":"Kochethu","year":"2007","journal-title":"Leukemia Res"},{"key":"10.1016\/j.biopha.2012.11.004_bib0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.59566\/IJBS.2008.4248","article-title":"TP53 codon 72 gene polymorphism paradox is associated with various carcinoma incidences, invasiveness and chemotherapy responses","volume":"4","author":"Lin","year":"2008","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.biopha.2012.11.004_bib0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000154324","article-title":"p53 polymorphism and haplotypes show distinct differences between major ethnic groups","volume":"46","author":"Sjalander","year":"1996","journal-title":"Hum Hered"},{"key":"10.1016\/j.biopha.2012.11.004_bib0185","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1084\/jem.20062476","article-title":"Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population","volume":"204","author":"Orsted","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.biopha.2012.11.004_bib0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cell.2005.01.028","article-title":"DNA repair, genome stability, and aging","volume":"20","author":"Lombard","year":"2005","journal-title":"Cell"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:13Z","timestamp":1760093413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0753332212001151"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.11.004","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}